TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS: EFFICACY AND SAFETY OF CHANGEOVER

TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS: EFFICACY AND SAFETY OF CHANGEOVER

Aim: to assess efficacy and safety of «changeover» to the second genetically engineered biological agent (GEBA) in patients with juvenile idiopathic arthritis (JIA) with resistance or intolerability to the first GEBA. Patients and methods: the results of retrospective observational research of effic...

Full description

Bibliographic Details
Main Authors: A. A. Baranov, E. I. Alexeeva, S. I. Valieva, T. M. Bzarova, E. V. Mitenko, R. V. Denisova, A. N. Fetisova, T. V. Sleptsova, K. B. Isaeva, E. G. Chistyakova, N. I. Taibulatov, A. M. Chomakhidze
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2014-01-01
Series:Вопросы современной педиатрии
Subjects:
ювенильный идиопатический артрит
переключение на другой биологический препарат
анти-фно-терапия
тоцилизумаб
ритуксимаб
Online Access:https://vsp.spr-journal.ru/jour/article/view/225

Internet

https://vsp.spr-journal.ru/jour/article/view/225

Similar Items